Drug intelligence / Profile preview

TPT0201

Development stage: Preclinical
Lead developer: Tetra Pharm Technologies
Modality: Small Molecules

Overview

**TPT0201** is a small molecule dual inhibitor of fatty acid amide hydrolase (**FAAH**) and monoacylglycerol lipase (**MAGL**) developed by Tetra Pharm Technologies ApS for neurodegeneration. It modulates receptors involved in stress and inflammation regulation while promoting neurogenesis to address amyloid beta formation and plaques linked to chronic stress in Alzheimer's disease. The drug targets pathogenesis in mild cognitive impairment (**MCI**) and Alzheimer's, with potential broader applications in dementias, and is currently in preclinical development.[3][5][7][9]

Targets

FAAHMGLL (Monoacylglycerol lipase)

Beyond the preview

Go deeper on TPT0201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPT0201.

Explore the full profile